I'rom Group Co Ltd
TSE:2372
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (4.5), the stock would be worth ¥242 914.1 (76% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 18.6 | ¥1 000 000 |
0%
|
| 3-Year Average | 4.5 | ¥242 914.1 |
-76%
|
| 5-Year Average | 2.7 | ¥142 886.24 |
-86%
|
| Industry Average | 8.3 | ¥446 278.15 |
-55%
|
| Country Average | 8.7 | ¥466 928.9 |
-53%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
I'rom Group Co Ltd
TSE:2372
|
33.8B JPY | 18.6 | 41.8 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
97.1B USD | 14 | 54.9 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.3B EUR | 7.8 | 13.4 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.4B USD | 0 | 12.1 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.9B EUR | 9.5 | 18.9 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23B EUR | 9.1 | 23.5 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.4B USD | 12.2 | 22.7 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.4B USD | 12.2 | 25.5 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.9B EUR | 5.4 | 11.2 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.7B USD | -30.7 | -28.1 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 7.2 | 14 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 6.7 |
| Median | 8.7 |
| 70th Percentile | 12.2 |
| Max | 214 699 781.2 |
Other Multiples
I'rom Group Co Ltd
Glance View
I'rom Group Co., Ltd. engages in the medical support business. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 810 full-time employees. The company went IPO on 2003-10-01. is engaged in medical fields such as regenerative medicine and gene discovery. The firm operates through four business segments. The SMO segment provides support services for contracting or substituting a part of the work related to conducting clinical trials from the conducting medical institution. The CRO segment provides all or part of clinical trial operations from pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies, as well as the provision of contract manufacture services. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services. The firm also provides business utilizing IT infrastructure.
